theMednetRegister
Int J Radiat Oncol Biol Phys 2024 Jan 1
Risk Modeling for Individualization of the FLAME Focal Boost Approach in External Beam Radiation Therapy for Patients With Localized Prostate Cancer.   

Related Questions

If using 26-fraction moderate hypofractionation, what dose do you use for the intraprostatic dominant nodule SIB?
The FLAME trial demonstrated a significant improvement in 5-year DFS, without any significant changes in overall toxicities, when patients being treat...
New comment by Radiation Oncologist at Christus St Vincent ( May 30, 2024)
Thank you. This sounds like a reasonable and safe plan to follow.
When treating prostate cancer with moderate hypo-fractionation, what urethral dose constraints do you consider when boosting the dominate intraprostatic lesion?
If delivering 300 cGy per fraction to the DIL, what urethra dose constraints to you use for 26 and 28 fraction regimens?
New comment by Radiation Oncologist at M.D. Anderson Cancer Center ( August 29, 2024)
Always appreciate your thoughtful and detailed responses @Krishnan! 
Copyright © 2024 theMednet
All Rights Reserved.